Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies (Q45066166)

9 December 2017

Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies (English)

1 reference

9 December 2017

Aspergillus terreus

1 reference

9

Hagop M Kantarjian

1 reference

9 December 2017

Dimitrios P Kontoyiannis

2

object named as

Dimitrios P Kontoyiannis

1 reference

9 December 2017

Ray Y Hachem

1

1 reference

9 December 2017

Maha R Boktour

3

1 reference

9 December 2017

Claude Afif

4

1 reference

9 December 2017

Catherine Cooksley

5

1 reference

9 December 2017

Gerald P Bodey

6

1 reference

9 December 2017

Ioannis Chatzinikolaou

7

1 reference

9 December 2017

Cheryl Perego

8

1 reference

9 December 2017

Issam I Raad

10

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

9 December 2017

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

9 December 2017

101

1 reference

9 December 2017

7

1 reference

9 December 2017

1594-1600

1 reference

Therapeutic outcome in invasive aspergillosis

9 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

Aspergillus terreus endophthalmitis in a patient with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

Invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Invasive aspergillosis in 2002: an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Infections with Aspergillus species.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Uncommon opportunistic fungi: new nosocomial threats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Aspergillus terreus during Hospital Renovation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Aspergillus terreus as a cause of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Epidemiology of Aspergillus terreus at a university hospital

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Antifungal drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Antifungal drug resistance of pathogenic fungi.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20554

7 January 2021

Identifiers

DOI

10.1002/CNCR.20554

1 reference

9 December 2017

1 reference